Loading organizations...
§ Private Profile · Hennigsdorf, Brandenburg, Germany
biopharmaceutical company developing Procizumab, an antibody therapy targeting DPP3 for circulatory shock.
4TEEN4 Pharmaceuticals is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies for critically ill patients, based in Hennigsdorf, Germany. The enterprise focuses on treating acute circulatory shock and cardiovascular failure by addressing the underlying biological drivers of these severe medical conditions. Its lead drug candidate, Procizumab, is designed to neutralize the circulating enzyme Dipeptidyl Peptidase 3 to restore heart and kidney function. The biotechnology firm has raised substantial capital to advance its clinical pipeline, recently extending its Series C financing round to €55 million following an initial €7 million Series A investment. Backed by lead investor Brandenburg Kapital and managed by an executive team including Joachim Struck and Kilian von Seldeneck, the company recently advanced its primary asset into Phase 1b/2a clinical trials. 4TEEN4 Pharmaceuticals was originally founded in 2013 by chief executive officer Andreas Bergmann.
4TEEN4 Pharmaceuticals has raised $71.0M across 2 funding rounds.
4TEEN4 Pharmaceuticals has raised $71.0M in total across 2 funding rounds.
4TEEN4 Pharmaceuticals has raised $71.0M across 2 funding rounds. Most recently, it raised $63.7M Series C Extension in November 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 13, 2025 | $63.7M Series C Plus | — | — | Announced |
| Jan 1, 2017 | $7.3M Series A | Claudia Dubro | — | Announced |
4TEEN4 Pharmaceuticals has raised $71.0M in total across 2 funding rounds.
4TEEN4 Pharmaceuticals's investors include Claudia Dubro.